Nordic Capital-backed LEO Pharma to acquire dersimelagon rights from Bain-owned Tanabe for $435m

LEO Pharma, which the release describes as a global leader in medical dermatology, serves close to 100 million patients in more than 70 countries annually.

DealsEuropeNorth AmericaUSHealthcareBriefs